BY101298

· Chengdu Baiyu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BY101298, covering 2024-12-18 to 2025-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors [Phase 1]